JavaScript NENÍ povolen !

Fischer-Barnicol, B* Dotaz Zobrazit nápovědu

1 záznamů v Medvik

Článek

Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis

BACKGROUND: There is limited evidence about the optimal length of washout when switching from natalizumab ...

Naegelin, Y
Autor Naegelin, Y Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Petersgraben 4, Basel 4031, Switzerland. Electronic address: Yvonne.naegelin@usb.ch
Rasenack, M
Autor Rasenack, M Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Petersgraben 4, Basel 4031, Switzerland
Andelova, M
Autor Andelova, M Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Petersgraben 4, Basel 4031, Switzerland Medical Image Analysis Center, University Hospital Basel, Marktgasse 8, Basel 4051, Switzerland Department of Neurology, First Faculty of Medicine, Charles University and General Hospital Prague, Ovocný trh 560/5, Prague 1 116 36, Czech Republic
Von Felten, S
Autor Von Felten, S Clinical Trial Unit, Department of Clinical Research, University Hospital Basel, Schanzenstrasse 55, Basel 4056, Switzerland
Fischer-Barnicol, B
Autor Fischer-Barnicol, B Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Petersgraben 4, Basel 4031, Switzerland
Amann, M
Autor Amann, M Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Petersgraben 4, Basel 4031, Switzerland Medical Image Analysis Center, University Hospital Basel, Marktgasse 8, Basel 4051, Switzerland Department of Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben 4, Basel 4031, Switzerland
Mehling, M
Autor Mehling, M Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Petersgraben 4, Basel 4031, Switzerland
Kappos, L
Autor Kappos, L Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Petersgraben 4, Basel 4031, Switzerland
Sprenger, T
Autor Sprenger, T Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Petersgraben 4, Basel 4031, Switzerland Medical Image Analysis Center, University Hospital Basel, Marktgasse 8, Basel 4051, Switzerland Department of Neurology, DKD HELIOS Klinik Wiesbaden, Aukammallee 33, 65191 Wiesbaden, Germany
Derfuss, T
Autor Derfuss, T Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Petersgraben 4, Basel 4031, Switzerland

Multiple sclerosis and related disorders. 2018 ; 25 (-) : 14-20. [pub] 20180706

Mult Scler Relat Disord
ISSN 2211-0356
Medvik
Zdroj

BACKGROUND: There is limited evidence about the optimal length of washout when switching from natalizumab to fingolimod. OBJECTIVE: To study if a washout period of 4 weeks is associated with less disease activity compared to 8 weeks. METHODS: 25 patients with Relapsing Remitting Multiple Sclerosis were included in an open label, prospective study with a follow-up of 108 weeks. The primary endpoint (PE) was defined as "time to first relapse or MRI disease activity up to week 56". In addition, a recurrent event analysis (REA) was performed up to week 108. RESULTS: The PE was not met (HR 0.67, 95% CI [0.22,1.97], p = 0.462). Number of relapses before stopping natalizumab was positively associated with the hazard of relapse (HR 3.91, p = 0.0117, 95% CI [1.36, 11.28]). The REA showed a reduction of the hazard to develop a relapse by 77% (HR 0.23, 95% CI [0.08, 0.69], p = 0.00854) in favor of the cohort with 4 weeks washout. CONCLUSIONS: Our study suggests that switching from natalizumab to fingolimod with a shorter washout of 4 weeks might reduce the risk of disease reactivation after switching.

Kolekce

Publikováno

Filtry

Fischer-Barnicol, B* Dotaz Zobrazit nápovědu

Fischer-Barnicol, B* Dotaz Zobrazit nápovědu

Upřesnit dle MeSH